Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
10:01am, Friday, 27'th Feb 2026
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
05:49am, Friday, 27'th Feb 2026
Hims stock has been under pressure this year. The company turned in solid Q4 results, but issued soft Q1 guidance.
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
04:48am, Friday, 27'th Feb 2026
Hims & Hers offers direct-to-consumer healthcare in a digitally native manner. The company is profitable, and its subscriber base is growing.
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore
07:17am, Thursday, 26'th Feb 2026
Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4. Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs.
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
07:18pm, Wednesday, 25'th Feb 2026
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIM
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
01:40pm, Wednesday, 25'th Feb 2026
Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.
Hims & Hers Health: The GLP-1 Party Is Over
11:07am, Wednesday, 25'th Feb 2026
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory
Hims & Hers Health: Don't Get Lost In The Weeds
04:02pm, Tuesday, 24'th Feb 2026
Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consen
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading
02:30pm, Tuesday, 24'th Feb 2026
Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
01:15pm, Tuesday, 24'th Feb 2026
HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.
Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results
12:46pm, Tuesday, 24'th Feb 2026
Hims & Hers Health Inc (NYSE: HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.
Stock Market Today: Major Indexes Rise After Tumbling Monday; AMD Stock Surges on Meta Chips Deal
10:30am, Tuesday, 24'th Feb 2026
Major stock indexes gained in early trading Tuesday, a day after plunging on worries about AI disruption and uncertainty over the state of President Donald Trump's tariffs.
KDP Beats & HIMS Misses Sales, QCOM Gains on Upgrades
10:30am, Tuesday, 24'th Feb 2026
Keurig Dr. Pepper (KDP) didn't fizzle out when it came to earnings, with Diane King Hall noting a beat Tuesday morning. Hims & Hers (HIMS) couldn't do the same as the telehealth company sees headwinds
Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard
09:24am, Tuesday, 24'th Feb 2026
Shares of Hims & Hers Health ( NYSE:HIMS ) are trading lower this morning after yesterday's earnings, and the reason is straightforward: guidance.
Hims & Hers Health After The GLP-1 Collapse
08:47am, Tuesday, 24'th Feb 2026
Hims & Hers Health's revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Operating cash flow reached $300M, with $929M in liquidity, reinforcing balance sheet strengt
